Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials

Lancet

Volumn 359, Issue 9302, 2002, Pages 189-198

  Boersma, Eric ^a   Harrington, Robert A ^b   Moliterno, David J ^c   White, Harvey ^d   Théroux, Pierre ^e   Van De Werf, Frans ^f   De Torbal, Anneke ^a   Armstrong, Paul W ^g   Wallentin, Lars C ^h   Wilcox, Robert G ⁱ   Simes, John ^j   Califf, Robert M ^b   Topol, Eric J ^c   Simoons, Maarten L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d GREEN LANE HOSPITAL   (New Zealand)

^e MONTREAL HEART INSTITUTE   (Canada)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁱ QUEEN S MEDICAL CENTRE   (United Kingdom)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; PLACEBO; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DECISION MAKING; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; ST SEGMENT ELEVATION; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037132843     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07442-1     Document Type: Article

References (31)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The capture study
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation
4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
5. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
6. Platelet glycoprotein IIB/IIIA receptor antagonists: An asset for treatment of unstable coronary syndromes and coronary intervention
7. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
8. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms
9. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network
10. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
11. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes
12. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
13. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: Design of a meta-analysis based on individual patient data
14. Acute coronary syndromes in the GUSTO-IIb trial: Prognostic insights and impact of recurrent ischemia
15. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: Results from an international trial of 9461 patients
16. Clinical trials in acute myocardial infarction: Should we adjust for baseline characteristics?
17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
18. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease
19. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
20. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
21. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: Prospective analysis from PURSUIT
22. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials
23. Randomised placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
24. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease
25. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
26. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
27. Direct thrombin inhibitors in acute coronary syndromes: A meta-analysis based on individual patients' data
28. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
29. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation: Recommendations of the Task Force of the European Society of Cardiology
30. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)